Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsLong-term efficacy and safety of raltegravir in the management of HIV infection.Clinical use of HIV integrase inhibitors: a systematic review and meta-analysisInitiation of antiretroviral therapy.Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or CBoosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Role of raltegravir in the management of HIV-1 infection.Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.Long-term safety from the raltegravir clinical development program.Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patientsP-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokineticsThe use of integrase inhibitors in treatment-experienced patients.Novel integrase inhibitors for HIV.Cost-effectiveness of raltegravir in HIV/AIDS.Renal toxicity associated with antiretroviral therapy.Next-generation integrase inhibitors : where to after raltegravir?Drug safety profile of integrase strand transfer inhibitors.Integrase Strand Transfer Inhibitors in HIV Therapy.Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.2014 Update of the drug resistance mutations in HIV-1Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda.3D-QSAR studies of quinoline ring derivatives as HIV-1 integrase inhibitors.
P2860
Q24628743-89EF6D4E-98CC-43A3-89E0-3943F3C033D9Q27686870-214D9AF9-2358-447E-BF58-3F057282464DQ28484930-B3032A7A-B20D-4A5F-ABA5-4F65968F8BFAQ30209635-BDB5D7B0-8702-4FEA-B118-3DED982C7AAAQ33940800-011C5252-5B75-4947-A19D-D23D0EE6D4CBQ34050693-4C8B42CD-E0EF-495B-B27A-BA4269E5B80DQ34520239-B7579D64-37F2-4794-BF42-545154740245Q35557318-7F2F9AB9-22EB-4B2F-BFF6-719BBF4FB030Q35689388-699711A3-C849-4D4F-8283-07199FDCBE34Q35701258-C2448802-A1FA-40BA-A243-6D67383EF5C1Q35770848-6FE6EC45-828E-4011-8896-884CF5D06442Q35896106-163F417B-3A5D-4E25-A164-D5B6272CA9F7Q36018635-F6AEBCF6-FF63-4C33-812E-BD090E2281DFQ37273923-2007B768-38DA-4689-9DEE-86E2D1836910Q37551700-E5C68603-57AB-4F99-B275-A02FBDB12D8EQ37644122-4738586F-8706-46C9-B2E3-D617B086193EQ37779774-C9C09770-E4BB-4F05-B769-3CFCD46347F6Q37958046-239A1A2E-3ABC-40B9-B1F0-1D91763E4DA2Q38031028-CF6A3A20-EB86-4288-BC17-7502B995B633Q38081866-439CC3DA-1B26-4AC0-A8C5-011F5CCEF22EQ38193524-E8F14013-B4D3-4DF4-B9A8-37054B7A196BQ38240974-422F6443-A2C2-4891-B8A0-BC368BC1409CQ38324557-FB70D20D-3AC1-45E8-999E-9C02FF89EB26Q39498339-3EAEF1F9-85EE-4985-B378-CBA721FB24C8Q43189964-A25F194F-6299-4F06-B848-5C98420CDC27Q45036770-75FFA2FA-DBA7-40F2-9402-4045EE4FB084Q47558450-40F65CC4-91F8-479A-A6FF-D25EFABE32AEQ54482597-782EE2EF-1604-4E21-86A9-B2EC06F10E77
P2860
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Long-term efficacy and safety ...... t options in a Phase II study.
@en
Long-term efficacy and safety ...... t options in a Phase II study.
@nl
type
label
Long-term efficacy and safety ...... t options in a Phase II study.
@en
Long-term efficacy and safety ...... t options in a Phase II study.
@nl
prefLabel
Long-term efficacy and safety ...... t options in a Phase II study.
@en
Long-term efficacy and safety ...... t options in a Phase II study.
@nl
P2093
P50
P1476
Long-term efficacy and safety ...... nt options in a Phase II study
@en
P2093
Adriano Lazzarin
Anne R Meibohm
Bach-Yen T Nguyen
Beatriz Grinsztejn
Charles J Gonzalez
Charlotte M Harvey
Christine Katlama
Daniel Vittecoq
P304
P356
10.1097/QAI.0B013E3181C9C967
P407
P577
2010-04-01T00:00:00Z